These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
690 related articles for article (PubMed ID: 19209096)
1. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R; Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096 [TBL] [Abstract][Full Text] [Related]
2. Meningococcal C vaccines: the Canadian experience. De Wals P Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070 [TBL] [Abstract][Full Text] [Related]
3. The impact of meningococcal serogroup C conjugate vaccine in Scotland. Mooney JD; Christie P; Robertson C; Clarke SC Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001 [TBL] [Abstract][Full Text] [Related]
4. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA; Clin Infect Dis; 2014 Nov; 59(9):1208-15. PubMed ID: 25069868 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896 [TBL] [Abstract][Full Text] [Related]
6. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Larrauri A; Cano R; García M; Mateo Sd Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059 [TBL] [Abstract][Full Text] [Related]
7. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment. Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749 [TBL] [Abstract][Full Text] [Related]
8. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine. Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA; Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381 [TBL] [Abstract][Full Text] [Related]
9. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China. Ni JD; Jin YH; Dai B; Wang XP; Liu DQ; Chen X; Zheng Y; Ye DQ Postgrad Med J; 2008 Feb; 84(988):87-92. PubMed ID: 18322129 [TBL] [Abstract][Full Text] [Related]
10. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695 [TBL] [Abstract][Full Text] [Related]
11. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
12. Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil. Cardoso CW; Pinto LL; Reis MG; Flannery B; Reis JN Vaccine; 2012 Aug; 30(37):5541-6. PubMed ID: 22749604 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis. Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136 [TBL] [Abstract][Full Text] [Related]
15. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil. Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE; Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013. Moraes C; Moraes JC; Silva GD; Duarte EC Mem Inst Oswaldo Cruz; 2017 Apr; 112(4):237-246. PubMed ID: 28327788 [TBL] [Abstract][Full Text] [Related]
18. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination]. Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849 [TBL] [Abstract][Full Text] [Related]
19. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Pace D Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410 [TBL] [Abstract][Full Text] [Related]
20. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]